Neuroblastoma is the most prevalent extracranial solid tumor among children and exhibits remarkable heterogeneity. The methylation of cytosine to form 5-methylcytosine (m5C) is the primary type of modification found in DNA and RNA. The NOL1/NOP2/sun (NSUN) family, specifically NSUN1, is responsible for the methylation process and has been shown to play a key role in cell differentiation and cancer development. Nevertheless, the impact of gene polymorphisms on neuroblastoma risk remains uncertain. Two selected gene polymorphisms (rs11834074 G>A and rs3764909 C>A) were genotyped via the TaqMan method in a study population consisting of 402 neuroblastoma patients and 473 cancer-free controls. The associations between two selected polymorphisms and neuroblastoma risk were evaluated using odds ratios (ORs) and 95% confidence intervals (CIs). Neither the overall analysis nor the stratification analysis revealed a significant correlation between these two polymorphisms and the risk of neuroblastoma (rs11834074 G>A, AA vs. GG: adjusted OR=0.99, 95% CI=0.58-1.67, =0.964; GA/AA vs. GG: adjusted OR=0.91, 95% CI=0.70-1.19, =0.478; AA vs. GG/GA: adjusted OR=1.04, 95% CI=0.63-1.73, =0.876; while for the rs3764909 C>A polymorphism, AA vs. CC: adjusted OR=1.03, 95% CI=0.66-1.62, =0.901; CA/AA vs. CC: adjusted OR=0.95, 95% CI=0.73-1.24, =0.710; AA vs. CC/CA: adjusted OR=1.07, 95% CI=0.70-1.64, =0.767). Collectively, these findings indicate that the two selected polymorphisms may not be associated with neuroblastoma susceptibility. However, further studies with larger sample sizes and additional potentially functional polymorphisms are needed to validate these results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685692 | PMC |
| http://dx.doi.org/10.7150/jca.103097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children's Oncology Group.
EJC Paediatr Oncol
December 2024
Dana-Farber / Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
Background: Response to induction chemotherapy has been shown to predict outcome in patients with high-risk neuroblastoma (HR-NB), with those achieving a complete response (CR) having superior outcomes.
Methods: We evaluated whether conventional prognostic factors remain prognostic in subsets of patients defined by response to induction. 1244 Patients from four COG high-risk trials were included.
Machine Learning Approaches for Neuroblastoma Risk Prediction and Stratification.
Crit Rev Oncog
January 2025
Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.
Machine learning (ML) holds great promise in advancing risk prediction and stratification for neuroblastoma, a highly heterogeneous pediatric cancer. By utilizing large-scale biological and clinical data, ML models can detect complex patterns that traditional approaches often overlook, enabling more personalized treatments and better patient outcomes. Various ML techniques, such as support vector machines, random forests, and deep learning, have shown superior performance in predicting survival, relapse, and treatment responses in neuroblastoma patients compared to conventional methods.
View Article and Find Full Text PDFDonor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.
Nat Med
January 2025
Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Allogeneic chimeric antigen receptor (CAR) T cells targeting disialoganglioside-GD2 (ALLO_GD2-CART01) could be a therapeutic option for patients with relapsed or refractory, high-risk neuroblastoma (r/r HR-NB) whose tumors did not respond to autologous GD2-CART01 or who have profound lymphopenia. We present a case series of five children with HR-NB refractory to more than three different lines of therapy who received ALLO_GD2-CART01 in a hospital exemption setting. Four of them had previously received allogeneic hematopoietic stem cell transplantation.
View Article and Find Full Text PDFFOXJ3, a novel tumor suppressor in neuroblastoma.
Mol Ther Oncol
March 2025
School of Interdisciplinary Informatics, University of Nebraska Omaha, 1110 South 67th Street, Omaha, NE 68182, USA.
Neuroblastoma (NB) poses a significant challenge in pediatric cancer care due to its aggressive nature and poor prognosis. While advances have been made in clinical treatments, therapy resistance remains a tough hurdle in NB treatment. While much research has focused on identifying oncogenes in NB, there has been less emphasis on understanding tumor suppressors.
View Article and Find Full Text PDFPromotion of cellular differentiation and DNA repair potential in brain cancer cells by Shankhpushpi, (Clitoria ternatea L.) with rasayana properties in vitro.
J Ayurveda Integr Med
January 2025
Centre for Ayurvedic Biology, Department of Ageing Research, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India. Electronic address:
Background: Brain ageing is accompanied by the diminution of neuronal plasticity, which is correlated with the inability to respond to loss of memory, various stress-induced stimuli, and increased risk of neurodegenerative disorders. In the recent past, plant based herbal medicines are of interest over synthetic drugs for therapeutic purposes due to lower side effects. The Indian traditional medicine Ayurveda describes several herbal remedies, such as rasayana (elixirs for rejuvenation), to treat many age-related diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!